Business
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM Canada ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Announces commercial focus on BioOxi\n \n TM\n \n bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities\n \n \n \n \n Reduces number of board members as part of geographic transition as a\n \n San Francisco Bay Area\n \n -based biotech company\n \n \n \n \n \n SUNNYVALE, Calif.\n \n \n ,\n \n \n Aug. 24, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, announces that having completed its transition to the\n \n San Francisco Bay Area\n \n and the commercial focus on its BioOxi platform, it has engaged an advisor to assist the Company with a review of opportunities to enhance shareholder value and unlock its intellectual property portfolio.\n \n \n \n \n \n \n \n \n \n \n Commercial Focus on BioOxi™ is Succeeding\n \n \n \n Willow has in recent months taken a number of steps to grow revenue and reduce costs. The Company has demonstrated executional success on commercial programs, including four new programs related to its BioOxi™ bio-oxidation platform technology launched in\n \n April 2023\n \n , and is now primarily focusing on partner-funded enzyme engineering engagements. This focus enables the Company to continue its cost reduction efforts while maximizing a faster path to nearer-term and potentially larger revenue opportunities, relative to its legacy strain engineering business.\n \n \n \n Transition to San Francisco Bay Area-Based Biotech Company Complete\n \n \n \n Willow has completed its transition as a\n \n San Francisco Bay Area\n \n -based biotech company. It has consolidated its operations, transitioning to a single, cost efficient facility in\n \n Sunnyvale, California\n \n ...